อ้างอิง ของ บูโพรพิออน

  1. ↑ "Bupropion". PubChem. Archived from the original on January 30, 2018.
  2. 1 2 3 4 5 6 7 8 "Zyban 150 mg prolonged release film-coated tablets – Summary of Product Characteristics (SPC)". electronic Medicines Compendium. GlaxoSmithKline UK. 1 August 2013. Archived from the original on July 20, 2017. สืบค้นเมื่อ 22 October 2013.
  3. 1 2 3 4 "Prexaton Bupropion hydrochloride PRODUCT INFORMATION". TGA eBusiness Services. Ascent Pharma Pty Ltd. 2 October 2012. Archived from the original on February 22, 2017. สืบค้นเมื่อ 22 October 2013.
  4. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 FDA Buproprion Label Last revised December 16, 2014 as described on the FDA Label Website. See that site for updates. Page accessed April 8, 2016
  5. ↑ Zhu, A. Z. X.; Zhou, Q.; Cox, L. S.; Ahluwalia, J. S.; Benowitz, N. L.; Tyndale, R. F. (3 September 2014). "Gene Variants in CYP2C19 Are Associated with Altered In Vivo Bupropion Pharmacokinetics but Not Bupropion-Assisted Smoking Cessation Outcomes". Drug Metabolism and Disposition. 42 (11): 1971–1977. doi:10.1124/dmd.114.060285. PMC 4201132. PMID 25187485.
  6. 1 2 Brunton, L; Chabner, B; Knollman, B (2010). Goodman and Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill Professional. ISBN 978-0-07-162442-8.
  7. ↑ Morton, Ian; Morton, I.K.; Hall, Judith M. (1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 57–. ISBN 978-0-7514-0499-9.
  8. ↑ Dictionary of Organic Compounds. CRC Press. pp. 104–. ISBN 978-0-412-54090-5.
  9. ↑ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 38–. ISBN 978-3-88763-075-1.
  10. ↑ Fava M, Rush AJ, Thase ME และคณะ (2005). "15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL". Prim Care Companion J Clin Psychiatry. 7 (3): 106–13. doi:10.4088/pcc.v07n0305. PMC 1163271. PMID 16027765.CS1 maint: Uses authors parameter (link)
  11. ↑ "Bupropion (By mouth)". PubMed Health. Bethesda, USA: National Institute of Health. 1 June 2014. Archived from the original on October 14, 2017. สืบค้นเมื่อ 18 July 2014.
  12. ↑ The INN originally assigned in 1974 by the World Health Organization was "amfebutamone". In 2000, the INN was reassigned as bupropion. See World Health Organization (2000). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 83" (PDF). WHO Drug Information. 14 (2). Archived from the original (PDF) on 1 February 2010. สืบค้นเมื่อ 22 June 2009.
  13. ↑ "First drug for seasonal depression". FDA Consum. 40 (5): 7. 2006. PMID 17328102.
  14. 1 2 Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
  15. 1 2 Joint Formulary Committee (2015). British National Formulary (BNF) (69 ed.). London, UK: Pharmaceutical Press. ISBN 978-0-85711-156-2.
  16. ↑ Wilkes, S (2008). "The use of bupropion SR in cigarette smoking cessation". International journal of chronic obstructive pulmonary disease. 3 (1): 45–53. doi:10.2147/copd.s1121. PMC 2528204. PMID 18488428.
  17. ↑ Hughes, JR; Stead, LF; Hartmann-Boyce, J; Cahill, K; Lancaster, T (8 January 2014). "Antidepressants for smoking cessation". The Cochrane Database of Systematic Reviews. 1: CD000031. doi:10.1002/14651858.CD000031.pub4. PMID 24402784.
  18. 1 2 Wu P, Wilson K, Dimoulas P, Mills EJ (2006). "Effectiveness of smoking cessation therapies: a systematic review and meta-analysis". BMC Public Health. 6: 300. doi:10.1186/1471-2458-6-300. PMC 1764891. PMID 17156479.CS1 maint: Uses authors parameter (link)
  19. 1 2 3 4 5 6 Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT (2006). "Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent". CNS Drug Rev. 12 (3–4): 178–207. doi:10.1111/j.1527-3458.2006.00178.x. PMID 17227286.CS1 maint: Uses authors parameter (link)
  20. ↑ Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S (2004). "A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor". Prim Care Companion J Clin Psychiatry. 6 (4): 159–166. doi:10.4088/PCC.v06n0403. PMC 514842. PMID 15361919.CS1 maint: Uses authors parameter (link)
  21. ↑ Foley KF, DeSanty KP, Kast RE (September 2006). "Bupropion: pharmacology and therapeutic applications". Expert Rev Neurother. 6 (9): 1249–65. doi:10.1586/14737175.6.9.1249. PMID 17009913.CS1 maint: Uses authors parameter (link)
  22. 1 2 Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC (April 2005). "Meta-analysis: pharmacologic treatment of obesity". Ann. Intern. Med. 142 (7): 532–46. doi:10.7326/0003-4819-142-7-200504050-00012. PMID 15809465.CS1 maint: Uses authors parameter (link)
  23. 1 2 Ryan DH, Bray GA (June 2013). "Pharmacologic treatment options for obesity: what is old is new again". Current hypertension reports. 15 (3): 182–9. doi:10.1007/s11906-013-0343-6. PMID 23625271.CS1 maint: Uses authors parameter (link)
  24. ↑ "Contrave label" (PDF). United States Food and Drug Administration. 10 September 2014. p. 1. Archived from the original (PDF) on May 18, 2017. สืบค้นเมื่อ 6 April 2015.
  25. ↑ Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM (September 2004). "Antidepressants for bipolar depression: a systematic review of randomized, controlled trials". Am J Psychiatry. 161 (9): 1537–47. doi:10.1176/appi.ajp.161.9.1537. PMID 15337640.CS1 maint: Uses authors parameter (link)
  26. ↑ Yatham LN, Kennedy SH, O'Donovan C, Parikh SV, MacQueen G, McIntyre RS, Sharma V, Beaulieu S (December 2006). "Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007". Bipolar Disord. 8 (6): 721–39. doi:10.1111/j.1399-5618.2006.00432.x. PMID 17156158.CS1 maint: Uses authors parameter (link)
  27. ↑ Kampman KM (June 2008). "The search for medications to treat stimulant dependence". Addict Sci Clin Pract. 4 (2): 28–35. doi:10.1151/ascp084228. PMC 2797110. PMID 18497715.
  28. ↑ Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ (2006). "Antidepressants and inflammatory bowel disease: a systematic review". Clin Pract Epidemiol Ment Health. 2: 24. doi:10.1186/1745-0179-2-24. PMC 1599716. PMID 16984660.CS1 maint: Uses authors parameter (link)
  29. ↑ Urquhart DM, Hoving JL, Assendelft WW, Roland M, van Tulder MW (2008). Urquhart DM, ed. "Antidepressants for non-specific low back pain". Cochrane Database Syst Rev (1): CD001703. doi:10.1002/14651858.CD001703.pub3. PMID 18253994.CS1 maint: Uses authors parameter (link)
  30. ↑ "FDA clears Cymbalta to treat chronic musculoskeletal pain". FDA Press Announcements. Food and Drug Administration. 4 November 2010. Archived from the original on December 19, 2017. สืบค้นเมื่อ 19 August 2013. The U.S. Food and Drug Administration ... approved Cymbalta (duloxetine hydrochloride) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain.
  31. ↑ Shah TH, Moradimehr A (August 2010). "Bupropion for the treatment of neuropathic pain". Am J Hosp Palliat Care. 27 (5): 333–6. doi:10.1177/1049909110361229. PMID 20185402.CS1 maint: Uses authors parameter (link)
  32. ↑ Maurizio Fava, A. John Rush, Michael E. Thase, Anita Clayton, Stephen M. Stahl, James F. Pradko, and J. Andrew Johnston (2005). "15 Years of Clinical Experience With Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL". J Clin Psychiatry. 7 (3): 106-113. PMC 1163271.CS1 maint: Multiple names: authors list (link)
  33. 1 2 3 Hales E, Yudofsky JA, eds. (2003). The American Psychiatric Press Textbook of Psychiatry. Washington, DC: American Psychiatric Publishing, Inc.CS1 maint: Uses editors parameter (link)
  34. ↑ Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R (2002). "Effects of psychotropic drugs on seizure threshold". Drug Saf. 25 (2): 91–110. doi:10.2165/00002018-200225020-00004. PMID 11888352.CS1 maint: Uses authors parameter (link)
  35. 1 2 Alper K, Schwartz KA, Kolts RL, Khan A (August 2007). "Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports". Biol. Psychiatry. 62 (4): 345–54. doi:10.1016/j.biopsych.2006.09.023. PMID 17223086.CS1 maint: Uses authors parameter (link)
  36. ↑ Taylor D (December 2008). "Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety". Acta Psychiatr Scand. 118 (6): 434–42. doi:10.1111/j.1600-0447.2008.01260.x. PMID 18785947.
  37. ↑ "Zyban (bupropion hydrochloride) – safety update". Medicines and Healthcare products Regulatory Agency. 24 July 2002. Archived from the original on 28 September 2007. สืบค้นเมื่อ 7 October 2006.
  38. ↑ Hubbard R, Lewis S, West J, Smith C, Godfrey C, Smeeth L, Farrington P, Britton J (October 2005). "Bupropion and the risk of sudden death: a self-controlled case-series analysis using The Health Improvement Network". Thorax. 60 (10): 848–50. doi:10.1136/thx.2005.041798. PMC 1747199. PMID 16055620.CS1 maint: Uses authors parameter (link)
  39. ↑ Branconnier RJ, Cole JO, Ghazvinian S; และคณะ (1983). "Clinical pharmacology of bupropion and imipramine in elderly depressives". J Clin Psychiatry. 44 (5 Pt 2): 130–3. PMID 6406441. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  40. ↑ Masco HL, Kiev A, Holloman LC; และคณะ (1994). "Safety and efficacy of bupropion and nortriptyline in outpatients with depression". Curr Ther Res. 55 (7): 851–63. doi:10.1016/S0011-393X (05) 80779-9 Check |doi= value (help). Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  41. ↑ Feighner J, Hendrickson G, Miller L; และคณะ (1986). "Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder". Clin Psychopharmacol. 6 (1): 27–32. PMID 3081600. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  42. ↑ Weisler RH, Johnston JA, Lineberry CG; และคณะ (1994). "Comparison ofbupropion and trazodone for the treatment of major depression". J Clin Psychopharmacol. 14 (3): 170–9. PMID 8027413. Unknown parameter |month= ignored (help); line feed character in |title= at position 14 (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
  43. ↑ Medical Economics (2005). Physician’s Desk Reference. Montvale, NJ: Thomson PDR. p. 1655–1659, 1659–1663, 1663–1668. ISBN 9781563634987.
  44. ↑ Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA. (1999). "A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline". Clin Ther. 21 (4): 643-58. doi:10.1016/S0149-2918 (00) 88317-4 Check |doi= value (help). PMID 10363731.CS1 maint: Multiple names: authors list (link)
  45. ↑ Kavoussi RJ, Segraves RT, Hughes AR, Ascher JA, Johnston JA. (1997). "Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients". J Clin Psychiatry. 58 (12): 532-7. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  46. ↑ Coleman CC, King BR, Bolden-Watson C, Book MJ, Segraves RT, Richard N, Ascher J, Batey S, Jamerson B, Metz A (2001). "A placebo-controlled comparison on sexual functioning of bupropion SR and fluoxetine". Clin Ther. 23 (7): 1040-58. PMID 11519769. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  47. ↑ Weihs KL, Settle EC Jr, Batey SR, Houser TL, Donahue RM, Ascher JA (2000). "Bupropion sustained-release versus paroxetine for the treatment of depression in the elderly". J Clin Psychiatry. 61 (3): 196-202. PMID 10817105. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  48. ↑
  49. ↑ Johnston JA, Lineberry CG, Frieden CS (1986). "Prevalence of psychosis, delusions, and hallucinations in clinical trials with bupropion". Am J Psychiatry. 143 (9): 1192–3. doi:10.1176/ajp.143.9.aj14391192. PMID 3092682. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
  50. 1 2 Levenson M, Holland C. "Antidepressants and suicidality in adults: statistical evaluation. (Presentation at Psychopharmacologic Drugs Advisory Committee; December 13, 2006)". U.S. Food and Drug Administration. Archived from the original on January 26, 2018. สืบค้นเมื่อ 13 May 2007.CS1 maint: Uses authors parameter (link)
  51. ↑ Hughes, JR; Stead, LF; Hartmann-Boyce, J; Cahill, K; Lancaster, T (8 January 2014). "Antidepressants for smoking cessation". The Cochrane Database of Systematic Reviews. 1: CD000031. doi:10.1002/14651858.CD000031.pub4. PMID 24402784.
  52. ↑ Commissioner, Office of the. "Safety Alerts for Human Medical Products - Chantix (varenicline) and Zyban (bupropion) : Drug Safety Communication – Mental Health Side Effects Revised". www.fda.gov (in อังกฤษ). Archived from the original on January 26, 2018. สืบค้นเมื่อ 20 December 2016.
  53. ↑ "Public Health Advisory: FDA requires new boxed warnings for the smoking cessation drugs Chantix and Zyban". U.S. Food and Drug Administration (FDA). 1 July 2009. Archived from the original on 19 October 2010. สืบค้นเมื่อ 3 July 2009.
  54. ↑ "The smoking cessation aids varenicline (marketed as Chantix) and bupropion (marketed as Zyban and generics) suicidal ideation and behavior" (PDF). Drug Safety Newsletter. U.S. Food and Drug Administration (FDA). 2 (1): 1–4. 2009.
  55. 1 2 3 Kumar S, Kodela S, Detweiler JG, Kim KY, Detweiler MB (November–December 2011). "Bupropion-induced psychosis: folklore or fact? A Systematic Review of the Literature". Gen Hosp Psychiatry. 33 (12): 612–7. doi:10.1016/j.genhosppsych.2011.07.001. PMID 21872337.CS1 maint: Uses authors parameter (link)
  56. ↑ Javelot T, Javelot H, Baratta A, Weiner L, Messaoudi M, Lemoine P (December 2010). "Acute psychotic disorders related to bupropion: review of the literature". Encephale. 36 (6): 461–71. doi:10.1016/j.encep.2010.01.005. PMID 21130229.CS1 maint: Uses authors parameter (link)
  57. ↑ Nemeroff CB, Schatzberg AF (2006). Essentials of clinical psychopharmacology. Washington, D.C: American Psychiatric Publishing. p. 146. ISBN 1-58562-243-5.CS1 maint: Uses authors parameter (link)
  58. ↑ Johnston JA (1999). "Discontinuation of Therapy With Bupropion SR". Prim Care Companion J Clin Psychiatry. 1 (5): 165. PMC 181084. PMID 15014680.
  59. ↑ Berigan TR (April 2002). "Bupropion-associated withdrawal symptoms revisited: a case report". Prim Care Companion J Clin Psychiatry. 4 (2): 78. doi:10.4088/PCC.v04n0208a. PMC 181231. PMID 15014751.
  60. ↑ Taylor, D; Carol, P; Shitij, K (2012). The Maudsley prescribing guidelines in psychiatry. West Sussex: Wiley-Blackwell. ISBN 978-0-470-97969-3.
  61. ↑ White N, Litovitz T, Clancy C (December 2008). "Suicidal antidepressant overdoses: a comparative analysis by antidepressant type". Journal of Medical Toxicology. 4 (4): 238–250. doi:10.1007/BF03161207. PMC 3550116. PMID 19031375.CS1 maint: Uses authors parameter (link)
  62. ↑ Beuhler MC, Spiller HA, Sasser HC (March 2010). "The outcome of unintentional pediatric bupropion ingestions: a NPDS database review". J Med Toxicol. 6 (1): 4–8. doi:10.1007/s13181-010-0027-4. PMC 3550434. PMID 20213217.CS1 maint: Uses authors parameter (link)
  63. 1 2 3 4 Jefferson JW, Pradko JF, Muir KT (November 2005). "Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations". Clin Ther. 27 (11): 1685–95. doi:10.1016/j.clinthera.2005.11.011. PMID 16368442.CS1 maint: Uses authors parameter (link)
  64. ↑ Fidel Vila-Rodriguez, Fidel; Dobek, Christine E; Blumberger, Daniel M; Downar, Jonathan; Daskalakis, Zafiris J (2015). "Risk of seizures in transcranial magnetic stimulation: a clinical review to inform consent process focused on bupropion". Neuropsychiatric Disease and Treatment: 2975. doi:10.2147/NDT.S91126. ISSN 1178-2021.
  65. ↑ Eric Wooltorton (2002). "Bupropion (Zyban, Wellbutrin SR) : reports of deaths, seizures, serum sickness" (PDF). CMAJ. 166 (1): 68. PMC 99232. Unknown parameter |month= ignored (help)
  66. ↑ Feinberg SS (2004). "Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication". J Clin Psychiatry. 65 (11): 1520–4. doi:10.4088/jcp.v65n1113. PMID 15554766.CS1 maint: Uses authors parameter (link)
  67. 1 2 Horst WD, Preskorn SH (December 1998). "Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion". J Affect Disord. 51 (3): 237–54. doi:10.1016/S0165-0327 (98) 00222-5 Check |doi= value (help). PMID 10333980.CS1 maint: Uses authors parameter (link)
  68. ↑ Johnston AJ, Ascher J, Leadbetter R, Schmith VD, Patel DK, Durcan M, Bentley B (2002). "Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation". Drugs. 62 Suppl 2: 11–24. doi:10.2165/00003495-200262002-00002. PMID 12109932.CS1 maint: Uses authors parameter (link)
  69. ↑ Xu H, Loboz KK, Gross AS, McLachlan AJ (March 2007). "Stereoselective analysis of hydroxybupropion and application to drug interaction studies". Chirality. 19 (3): 163–70. doi:10.1002/chir.20356. PMID 17167747.CS1 maint: Uses authors parameter (link)
  70. ↑ Bondarev ML, Bondareva TS, Young R, Glennon RA (August 2003). "Behavioral and biochemical investigations of bupropion metabolites". Eur. J. Pharmacol. 474 (1): 85–93. doi:10.1016/S0014-2999 (03) 02010-7 Check |doi= value (help). PMID 12909199.CS1 maint: Uses authors parameter (link)
  71. ↑ Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S, Lukas RJ, Martin BR (September 2004). "Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors". Mol. Pharmacol. 66 (3): 675–82. doi:10.1124/mol.104.001313. PMID 15322260.CS1 maint: Uses authors parameter (link)
  72. 1 2 3 4 5 6 7
  73. 1 2 3 4 5 6 Lemke, Thomas L.; Williams, David A. (24 January 2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 611–613. ISBN 978-1-60913-345-0.
  74. ↑ Arias HR, Santamaría A, Ali SF (2009). "Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion". Int. Rev. Neurobiol. 88: 223–55. doi:10.1016/S0074-7742 (09) 88009-4 Check |doi= value (help). PMID 19897080.CS1 maint: Uses authors parameter (link)
  75. ↑ Labbate, Lawrence A.; Fava, Maurizio; Rosenbaum, Jerrold F.; Arana, George W. (28 March 2012). Handbook of Psychiatric Drug Therapy. Lippincott Williams & Wilkins. pp. 64–. ISBN 978-1-4511-5307-1.
  76. 1 2 Warner C, Shoaib M (September 2005). "How does bupropion work as a smoking cessation aid?". Addict Biol. 10 (3): 219–31. doi:10.1080/13556210500222670. PMID 16109583.CS1 maint: Uses authors parameter (link)
  77. ↑ Ascher JA, Cole JO, Colin JN และคณะ (September 1995). "Bupropion: a review of its mechanism of antidepressant activity". J Clin Psychiatry. 56 (9): 395–401. PMID 7665537.CS1 maint: Uses authors parameter (link)
  78. 1 2 Stahl SM (March 2017). "Bupropion". Prescriber's Guide: Stahl's Essential Psychopharmacology (6th ed.). Cambridge, United Kingdom: Cambridge University Press. pp. 107–112. ISBN 9781108228749. สืบค้นเมื่อ 5 January 2018.CS1 maint: Uses authors parameter (link)
  79. 1 2 "Bupropion: Biological activity". IUPHAR/BPS Guide to Pharmacology. International Union of Basic and Clinical Pharmacology. Archived from the original on January 6, 2018. สืบค้นเมื่อ 5 January 2018.
    Target: DAT
    Type: Inhibitor
    Action: Inhibition
    Affinity: 6.3
    Units: pIC50 ... (IC50 4.43x10−7 M)
  80. 1 2 Simonsen U, Comerma-Steffensen S, Andersson KE (October 2016). "Modulation of Dopaminergic Pathways to Treat Erectile Dysfunction". Basic & Clinical Pharmacology & Toxicology. 119 Suppl 3: 63–74. doi:10.1111/bcpt.12653. PMID 27541930. Bupropion is so far the only antidepressant with some selectivity for DAT over NET and SERT with Ki values (nM) of, respectively, 526, 52,600 and 9100 for the three transporters.CS1 maint: Uses authors parameter (link)
  81. ↑ Carroll FI, Blough BE, Mascarella SW, Navarro HA, Lukas RJ, Damaj MI (2014). "Bupropion and bupropion analogs as treatments for CNS disorders". Adv. Pharmacol. 69: 177–216. doi:10.1016/B978-0-12-420118-7.00005-6. PMID 24484978.CS1 maint: Uses authors parameter (link)
  82. ↑ Arias HR (2009). "Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions?". Int. J. Biochem. Cell Biol. 41 (11): 2098–108. doi:10.1016/j.biocel.2009.05.015. PMID 19497387.CS1 maint: Uses authors parameter (link)
  83. ↑ Damaj MI, Carroll FI, Eaton JB และคณะ (September 2004). "Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors". Mol. Pharmacol. 66 (3): 675–82. doi:10.1124/mol.104.001313. PMID 15322260.CS1 maint: Uses authors parameter (link) CS1 maint: Explicit use of et al. (link)
  84. ↑ Zhu AZ, Cox LS, Nollen N และคณะ (December 2012). "CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion". Clin. Pharmacol. Ther. 92 (6): 771–7. doi:10.1038/clpt.2012.186. PMC 3729209. PMID 23149928.CS1 maint: Uses authors parameter (link) CS1 maint: Explicit use of et al. (link)
  85. ↑ Foxhall, Lewis E.; Rodriguez, Maria Alma (2014). Advances in Cancer Survivorship Management. Springer. pp. 265–. ISBN 978-1-4939-0986-5.
  86. ↑ Johnson, Bankole A. (10 October 2010). Addiction Medicine: Science and Practice. Springer Science & Business Media. pp. 433–. ISBN 978-1-4419-0338-9.
  87. ↑ Pandhare A, Pappu AS, Wilms H, Blanton MP, Jansen M (2016). "The antidepressant bupropion is a negative allosteric modulator of serotonin type 3A receptors". Neuropharmacology. 113 (Pt A): 89–99. doi:10.1016/j.neuropharm.2016.09.021. PMID 27671323.CS1 maint: Uses authors parameter (link)
  88. ↑ "GlaxoSmithKline (GSK) Reviews Novel Therapeutics For CNS Disorders And Confirms Strong Pipeline Momentum" (Press release). PRNewswire. 23 November 2004. Archived from the original on 28 September 2007. สืบค้นเมื่อ 18 August 2007.
  89. ↑ GlaxoSmithKline (July 26, 2006). "Pipeline Update" (PDF). Archived from the original (PDF) on 27 September 2007.   (136 KB). Press release. Retrieved on 18 August 2007.
  90. 1 2 Meyer A, Vuorinen A, Zielinska AE, Strajhar P, Lavery GG, Schuster D, Odermatt A (September 2013). "Formation of threohydrobupropion from bupropion is dependent on 11β-hydroxysteroid dehydrogenase 1". Drug metabolism and disposition: the biological fate of chemicals. 41 (9): 1671–8. doi:10.1124/dmd.113.052936. PMC 3876805. PMID 23804523.CS1 maint: Uses authors parameter (link)
  91. ↑ Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, Greenblatt DJ, Court MH (April 2004). "Pharmacogenetic determinants of inter-individual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes". Pharmacogenetics. 14 (4): 225–38. doi:10.1097/00008571-200404000-00002. PMID 15083067.CS1 maint: Uses authors parameter (link)
  92. ↑ Preskorn SH (1991). "Should bupropion dosage be adjusted based upon therapeutic drug monitoring?". Psychopharmacol Bull. 27 (4): 637–43. PMID 1813908.
  93. ↑ Weintraub D, Linder MW (2000). "Amphetamine positive toxicology screen secondary to bupropion". Depress Anxiety. 12 (1): 53–4. doi:10.1002/1520-6394 (2000) 12:1<53::AID-DA8>3.0.CO;2-4 Check |doi= value (help). PMID 10999247.CS1 maint: Uses authors parameter (link)
  94. ↑ Nixon AL, Long WH, Puopolo PR, Flood JG (June 1995). "Bupropion metabolites produce false-positive urine amphetamine results". Clin. Chem. 41 (6 Pt 1): 955–6. PMID 7768026.CS1 maint: Uses authors parameter (link)
  95. ↑ Casey, E.R.; Scott, M.G.; Tang, S.; Mullins, M.E. (Jun 2011). "Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay". J Med Toxicol. 7: 105–8. doi:10.1007/s13181-010-0131-5. PMC 3724447. PMID 21191682.
  96. 1 2 3 Sager JE, Choiniere JR, Chang J, Stephenson-Famy A, Nelson WL, Isoherranen N (2016). "Identification and Structural Characterization of Three New Metabolites of Bupropion in Humans". ACS Med Chem Lett. 7 (8): 791–6. doi:10.1021/acsmedchemlett.6b00189. PMID 27660681.CS1 maint: Uses authors parameter (link)
  97. 1 2 Mehta NB (25 June 1974). "United States Patent 3,819,706: Meta-chloro substituted α-butylamino-propiophenones". USPTO. Archived from the original on November 7, 2017. สืบค้นเมื่อ 2 June 2008.
  98. ↑ Perrine DM, Ross JT, Nervi SJ, Zimmerman RH (2000). "A Short, One-Pot Synthesis of Bupropion (Zyban, Wellbutrin)". Journal of Chemical Education. 77 (11): 1479. Bibcode:2000JChEd..77.1479P. doi:10.1021/ed077p1479.CS1 maint: Uses authors parameter (link)
  99. ↑ "Wellbutrin entry in the Orange Book". U.S. Food and Drug Administration Center for Drug Evaluation and Research. Archived from the original on February 11, 2017. สืบค้นเมื่อ 18 August 2007.
  100. ↑ "Bupropion (Wellbutrin)". eMedExpert.com. 31 March 2008. สืบค้นเมื่อ 20 August 2013.
  101. 1 2 Whitten L (April 2006). "Bupropion helps people with schizophrenia quit smoking". National Institute on Drug Abuse Research Findings. 20 (5). Archived from the original on 5 August 2007. สืบค้นเมื่อ 27 May 2013.
  102. ↑ "Seasonal affective disorder drug Wellbutrin XL wins approval". CNN. 14 June 2006. Archived from the original on 30 June 2007. สืบค้นเมื่อ 19 August 2007.
  103. ↑ "Zyban : sevrage tabagique et sécurité d'emploi" [Zyban: smoking cessation and job security] (Press release) (in French). Agence française de sécurité sanitaire des produits de santé. 18 January 2002. Archived from the original on 23 July 2011. สืบค้นเมื่อ 25 January 2011.CS1 maint: Unrecognized language (link)
  104. ↑ GlaxoSmithKline (16 January 2007). "GlaxoSmithKline receives first European approval for Wellbutrin XR" (Press release). GlaxoSmithKline. Archived from the original on 27 December 2010. สืบค้นเมื่อ 25 January 2011.
  105. ↑ "Generic drug equality questioned". สืบค้นเมื่อ 13 October 2007.
  106. ↑ Stenson, Jacqueline (12 October 2007). "Report questions generic antidepressant". msnbc.com. Archived from the original on October 12, 2007. สืบค้นเมื่อ 13 October 2007.
  107. ↑ "Review of therapeutic equivalence: generic bupropion XL 300 mg and Wellbutrin XL 300 mg". Archived from the original on 6 June 2011. สืบค้นเมื่อ 19 April 2008.
  108. 1 2 "Budeprion XL 300 mg not therapeutically equivalent to Wellbutrin XL 300 mg" (Press release). FDA. 3 October 2012. สืบค้นเมื่อ 23 March 2013.
  109. ↑ "FDA Update". FDA. October 2013. Archived from the original on January 26, 2018. สืบค้นเมื่อ 15 June 2015.
  110. ↑ Waknine, Yael (8 May 2008). "FDA Approvals: Advair, Relistor, Aplenzin". Medscape. สืบค้นเมื่อ 9 May 2008.
  111. ↑ Thomas K, Schmidt MS (2 July 2012). "Glaxo agrees to pay $3 billion in fraud settlement". The New York Times.CS1 maint: Uses authors parameter (link)
  112. ↑ "Abuse potential of common psychiatric medications". Substance abuse treatment for persons with HIV/AIDS. Treatment Improvement Protocol. Rockville: Substance Abuse and Mental Health Services Administration. pp. 83–4.
  113. ↑ Lile JA, Nader MA (2003). "The abuse liability and therapeutic potential of drugs evaluated for cocaine addiction as predicted by animal models". Current Neuropharmacology. 1: 21–46. doi:10.2174/1570159033360566.CS1 maint: Uses authors parameter (link)
  114. ↑ Antidepressant Wellbutrin becomes 'poor man's cocaine' on Toronto streets Global News 18 September 2013.
  115. ↑ Philipps, DeAnne (February 2012). "Wellbutrin®: Misuse and Abuse by Incarcerated Individuals". Journal of Addictions Nursing. 23 (1): 65–69. doi:10.3109/10884602.2011.647838. PMID 22468662.
  116. ↑ Baribeau, Danielle; Araki, Keyghobad Farid (May–June 2013). "Intravenous Bupropion: A Previously Undocumented Method of Abuse of a Commonly Prescribed Antidepressant Agent". Journal of Addiction Medicine. 7 (3): 216–217. doi:10.1097/ADM.0b013e3182824863. PMID 23519045.CS1 maint: Uses authors parameter (link)
  117. ↑ I.K. Morton,Judith M. Hall (2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Berlin, Germany: Springer Science & Business Media. p. 57. ISBN 9789401059077.
  118. ↑ Holm KJ, Spencer CM (2000). "Bupropion: a review of its use in the management of smoking cessation". Drugs. 59 (4): 1007–24. PMID 10804045. Archived from the original on July 10, 2015. Unknown parameter |month= ignored (help)
  119. 1 2 3 "Bupropion International Brands". Drugs.com. Archived from the original on June 14, 2016. สืบค้นเมื่อ 1 June 2017.


ระบบประสาท
ส่วนกลาง
กระตุ้น
ยับยั้งตัวรับ
แคนนาบินอยด์
อื่นๆ
ส่วนปลาย
สารกระตุ้นโดปามีน
สารกระตุ้นเมลาโนคอร์ติน
สารที่ยับยั้งเอนไซม์ฟอสโฟ-
ไดเอสเทอเรสชนิดที่ 5
ฮอร์โมนเพศ
อื่นๆ
ทางเดินอาหาร/
เมแทบอลิซึม (A)
เลือดและอวัยวะ
สร้างเลือด (B)
ระบบหัวใจ
และหลอดเลือด (C)
ยารักษาโรคหัวใจ/ยาแก้อาการปวดเค้นหัวใจ (คาร์ดิแอคไกลโคไซด์ , ยาต้านภาวะหัวใจเสียจังหวะ , ยากระตุ้นหัวใจ) • ยาลดความดัน • ยาขับปัสสาวะ • สารขยายหลอดเลือด • เบต้า บล็อกเกอร์ • แคลเซียมแชนแนลบล็อกเกอร์ • ระบบเรนิน-แองจิโอเทนซิน (เอซีอีอินฮิบิเตอร์ , แองกิโอเทนซินรีเซพเตอร์บล๊อคเกอร์ , เรนินอินฮิบิเตอร์) • ยาลดไขมันในเส้นเลือด (สแตติน , ไฟเบรต , ไบล์แอซิดซีเควสแตรนต์)
ผิวหนัง (D)
ระบบสืบพันธุ์ (G)
ระบบต่อมไร้ท่อ (H)
การติดเชื้อและ
การติดเชื้อปรสิต (J, P, QI)
มะเร็ง (L01-L02)
โรคทางระบบ
ภูมิคุ้มกัน (L03-L04)
กล้ามเนื้อ กระดูก และข้อต่อ (M)
สมองและระบบประสาท (N)
ระบบทางเดินหายใจ (R)
อวัยวะรับความรู้สึก (S)
อื่น ๆ (V)

แหล่งที่มา

WikiPedia: บูโพรพิออน http://82.77.46.154/gsdldata/collect/whodruginfo/i... http://globalnews.ca/news/846576/antidepressant-we... http://www.biospace.com/news_story.aspx?StoryID=18... http://www.chemspider.com/Chemical-Structure.431.h... http://www.clinicaltherapeutics.com/article/S0149-... http://www.cnn.com/HEALTH/library/DI/00069.html http://www.emedexpert.com/facts/bupropion-facts.sh... http://www.gsk.com/investors/reports/gsk_q22006/q2... http://www.gsk.com/media/pressreleases/2007/2007_0... http://www.medscape.com/viewarticle/574187